Prostate Cancer

In both racial cohorts, median MFS was not reached in the darolutamide group.

“Looking at our overall results, not surprisingly, we can show a clear benefit of ARPIs on overall survival," says David Fisher, MSc, MA.

The investigators reported an HR for OS of 0.796 (95% CI, 0.661-0.958; 2-sided P = .0155) for talazoparib/enzalutamide vs enzalutamide/placebo.

The software generates heatmaps to help identify prostatic tumors that may have been missed on initial reads.

"The management of advanced prostate cancer has evolved significantly, driven in part by the integration of diverse biomarkers that guide treatment decisions from diagnosis through progression," says Nedim Ruhotina, MD.

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

The primary end point is 12-month radiographic progression-free survival.

A list of facts and trends to know about the current landscape of urologic cancer management and research in the US.

The data also showed that mortality plateaued in recent years despite declining in years prior.

The incidence of late grade 2 or greater GU toxicity at 5 years was 12.5% among those who did experience acute toxicity vs 7.5% among those who did not.

“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.

According to the authors, these findings highlight the need to more effectively include Black men in prostate cancer research.

“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH.

Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.

At 25 weeks, FACT-P total score remained comparable between the arms.

"If you can do this surgery well, patients actually go back to living a normal life, and they're immensely, immensely happy," says Jaspreet S. Sandhu, MD.

"We are trying to develop epigenetic biomarkers that can predict patients that are starting to progress to neuroendocrine prostate cancer," says Jindan Yu, MD, PhD.

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.

The PDUFA target action date has been set for August 29, 2025.

“Another aspect is how to make this more and more complex diagnostic chain for prostate cancer work in practice, because we now have so [many] more tools than we had a decade ago,” says Tobias Nordström, MD, PhD.

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

“The key take home message of that study was that having assumptions about basic medical terminology that we think are simple may actually leave patients confused,” says Vikram M. Narayan, MD.

“If there's enough radiation, then the cells can't repair themselves and die because of the radiation,” says Scott T. Tagawa, MD, MS, FACP, FASCO.

The application is supported by data from the pivotal phase 3 ARANOTE trial.

Catch up on all the notable drug and device approvals in urology over the past year.

As the year comes to a close, we revisit some of this year’s top video content from Urology Times.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

"There's a number of emerging modalities in the primary focal ablation space that are in trial at this time," says Kara L. Watts, MD.

The alert was issued to clarify that the devices should not be used for suction and irrigation.